KR20160008459A

KR20160008459A - a composition comprising an extract of Gynura procumbens as an active ingredient for preventing or treating inflammation or allergy

Info

Publication number: KR20160008459A
Application number: KR1020150094419A
Authority: KR
Inventors: 박창용; 최미숙; 오진희; 김동순
Original assignee: 박창용; 오진희; 최미숙
Priority date: 2014-07-14
Filing date: 2015-07-02
Publication date: 2016-01-22
Also published as: KR101764756B1

Abstract

The present invention relates to a composition for preventing or treating an inflammatory or allergic disease comprising an extract of Aspergillus oryzae as an active ingredient. The extract of Oryxpans according to the present invention was an experiment for inhibiting NO production using LPS-stimulated rat peritoneal macrophages (Experimental Example 1); Inhibition of TNF-a production (Experimental Example 2); Test for the inhibition of histamine secretion induced by Compound 48/80 in mast cells (Experimental Example 3); And at least one animal model of atopic dermatitis induced by DNCB, it is possible to provide a pharmaceutical composition for preventing or treating an inflammatory or allergic disease by confirming that it has excellent efficacy against inflammation and allergic diseases, especially atopic dermatitis and allergic dermatitis, It is useful as a food or a health supplement.

Description

[0001] The present invention relates to a composition for preventing or treating an inflammatory or allergic disease which contains an extract of Aspergillus oryzae as an active ingredient,

The present invention relates to a composition for the prevention and treatment of inflammation or allergic diseases containing an extract of Aspergillus as an active ingredient.

[Literature 1] Robert C. & Kupper T. S Inflammatory skin disease, T cells, and immune surveillance. N Engl. J. Med. 341, 1817-1828, 1999

[Document 2] Hwang, S. T. Mechanisms of T cell homing to skin. Adv. Dermatol. 17, 211-241, 2001

[Patent Document 3] Akidis, C. A et al., T cell and T cell derived cytokines as pathologic factors in the non-allergic form of atopic dermatitis J Invest Dermatol 113, 628-634 (1999)

[4] Leung D. Y. & Bieber, T. Atopic dermatitis Lancet 361, 151-160 (2003)

[Literature 5] Dillon S. R et al., Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 5: 752-759 (2004)

[Literature 6] Dieveu C. et al., GPL, a novel cytokine receptor related GP130 and leukemia inhibitory factor receptor. J boil Chem. 278, 49850-49859 (2003)

IL-31 and IL-31 in atopic and allergic contact dermatitis, J Allergy Clin Immunol 118: 930-937 (2006) (2008), Neis M. M et al., Enhanced expression levels of IL-

[Literature 8] Matsuda, H et al., Development of atopic dermatitis like skin lesions with IgE hyperproduction in NC / Nga mice. Int Immunol. 9, 461-466, 1997

[9] Takaoka, A., Arai, I., et al., Involvement of IL-31 on scratching behavior in NC / Nga mice with atopic like dermatitis. Exp Dermatol 15: 161, 2006

[Literature 10] Cheung P. F et al., Activation of human eosinophil and epidermal keratinocytes by Th2 cytokine IL-31: Implication for the immunopathogenesis of atopic dermatitis. Int Immunol 22 (6); 453-467, 2010

[Literature 11] Asnis L. A et al., Cutaneous reaction to recombinant cytokine therapy J Am Acad Dermatol 24; 915-926, 1995

[Literature 12] Encyclopedia of Chinese Medicine, Shanghai Science and Technology Publishing Co., Ltd., Suzhou, Vol. (2), p1138, 2367, 1984

[Literature 13] Molecular Immunology, Volume 46, Issues 1112, July 2009, Pages 2413-2418

[Literature 14] European Journal of Pharmacology, Volume 612, Issues 13, 10 June 2009, Pages 122-130

[Literature 15] Journal of Acupuncture and Meridian Studies, Volume 6, Issue 2, April 2013, Pages 98-109

The present invention relates to a pharmaceutical composition and a health functional food for preventing and treating an allergic disease containing an extract of Aspergillus oryzae as an active ingredient.

In general, an inflammatory reaction is a defensive reaction process of a living body that attempts to repair and regenerate a damaged region when an invasion of biological changes occurs in the cell or tissue of the living body. Thus, these series of reactions include localized blood vessels, various tissue cells of body fluids, and immune-mediated cells. With the recent development of molecular biology, inflammatory diseases have been attempted to be understood at the molecular level of cytokine, and the factors affecting these diseases are also being clarified one by one.

Allergic reactions can be classified into four types according to the type of reaction: type I, type II, type III, and type IV, or type I, type II according to the time until onset after re- Type III and Type III allergies are called immediate allergies and Type IV allergies can be classified as delayed allergies.

Among them, type I allergy is a reaction involving IgE antibody, which is called anaphylactoid type allergy, and includes allergic rhinitis such as bronchial asthma, atopic diseases (dermatitis, enteritis), hay fever, allergic conjunctivitis, .

To counteract external stimuli and antigens, various immune cells are present in the skin, forming a complex network of them and maintaining homeostasis (Robert C. & Kupper T. S Inflammatory skin disease, T cells, and immune surveillance. J. Med 341, 1817-1828, 1999 The epithelial tissues are mainly composed of keratinocytes, and there are Langerhans cells, T cells and macrophages (2.Hwang, ST Mechanisms of T cell homing to skin. Adv. Dermatol.17, 211-241, 2001 Most skin diseases are characterized by inflammatory responses by immune cells and are accompanied by clinical symptoms such as itching, edema, erythema, eczema, and scaling. Recognition of the invaded antigen secretes chemoattractant factors, eosinophils and mast cells, and activates T cells to aggregate into damaged tissue. Specific cytokines secreted from activated T cells are overexpressed (3 Akidis, CA et al., T Cell and T cell-derived cytokines as pathologic factors in the non-allergic form of atopic dermatitis J Invest Dermatol 113, 628-634 (1999) . They cause itching and increase the inflow of inflammatory cells, resulting in allergic or non-allergic skin diseases such as psoriasis as well as atopic dermatitis and contact dermatitis (Leung DY & Bieber, T. Atopic dermatitis Lancet 361 IL-31 is produced in activated T cells (more expressed in Th2 cells), belonging to the IL-6 cytokine family (5. Dillon S. R et al. , Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 5: 752-759 (2004). IL-31 receptors are composed of gp-130 receptors (GPL, or IL-31RA) and oncostatin M receptors (OSMR), and are always present in epithelial cells and keratinocytes (Dieveu C. et al., GPL, IL-31 expression was significantly increased in skin tissues of patients with atopic dermatitis and IL-4 and IL-13 were significantly increased in the atopic dermatitis patients IL-4 and IL-31 in atopic and allergic contact dermatitis, J Allergy Clin Immunol 118: 930-937 (1997)). 2006). These Th2 cytokines act on B cells to increase the production of IgE, and IgE binds to receptors present in mast cells and mediates histamine release, resulting in inflammatory reactions and itching (8. Matsuda, H et al., Development of atopic dermatitis like skin lesions wit h IgE hyperproduction in NC / Nga mice, Int Immunol 9, 461-466, 1997), and that the expression of IL-31 receptor is increased in epithelial and keratinocytes from patients with atopic dermatitis and in macrophages isolated from patients Transgenic mice that inject IL-31 into the skin of mice or persistently express IL-31 exhibit severe itching, and significant inflow of eosinophils and mast cells into the skin tissue is observed, indicating that it is a major pathologic factor deepening dermatitis (9) Takaoka, A., Arai, I. et al., Involvement of IL-31 on scratching behavior in NC / Nga mice with atopic like dermatitis. Exp Dermatol 15: 161, 2006; 10. Cheung P. F et al., Activation of human eosinophil and epidermal keratinocytes by Th2 cytokine IL-31: Implication for the immunopathogenesis of atopic dermatitis. Int Immunol 22 (6); 453-467, 2010). Meanwhile, IL-2 secreted from T cells stimulates and activates the proliferation of T cells. It is known that cancer patients treated with IL-2 exhibit severe skin pruritus and form swelling, erythema, necrosis, urticaria and blistering of the skin tissue (Asnis LA et al., Cutaneous reaction to recombinant cytokine therapy J Am Acad Dermatol 24; 915-926, 1995).

Atopy is a chronic skin disease that involves dry skin, keratinization, and itching. Approximately 15% of the population is atopic, with about 20% of these children being infected. In the past, atopy began in infancy and early childhood, and the disease gradually grew with the progress of the disease, but disappear before the age of 7 to 8 years, since the 1970s due to rapid industrialization caused by the pollution rate is increasing every year, This period continues until adolescence and adulthood, and the number of new cases that have become worse or worse after adolescence has also increased remarkably. The exact pathophysiology of atopy has not yet been fully elucidated, but environmental factors are thought to be involved with genetic factors. Serious atopy is a serious social problem, even leading to social problems such as employment or marriage, and it can develop into mental stress, which can lead to gangrene or depression.

Although atopy is a serious social and medical problem, the pathophysiology has not been accurately identified, so there is no effective treatment until now. Conventional atopic treatments include steroids, antibiotics, etc. However, currently used therapies have little or no therapeutic effect and are widely used in medical devices, cosmetics, or herbal remedies. As described above, considering that atopy is intensively developed in infants, safe medicines are now in desperate need. Since atopic asthma or allergic rhinitis may develop and cause various immune diseases in the body, proper early treatment .

On the other hand, Gynura procumbens is a perennial plant belonging to Asteraceae distributed in the Philippines, Thailand, Indonesia, India, Japan and China. It has one stem, , The leaves are green in color, the shape is ovate, the upper part of the leaf is pointed, and the lower part is oval. Leaf edges are flat or wavy. Both sides of leaf are soft and sharp. According to a study by Osaka Pharmaceutical University in Japan, it is said that the beginning of the beginning of the fall contains four times as much germanium as ginseng and many kinds of natural organic ingredients, and aging prevention And is effective for thrombolysis, cancer prevention, blood sugar, blood pressure, cholesterol regulation, etc. It is known to be used for treating bruises, arthralgia, bronchitis and pulmonary tuberculosis. (Chinese Traditional Medicine Dictionary, Shanghai Science and Technology Publishing Co., Ltd., Suzhou, Vol. (2), p1138, 2367, 1984).

However, none of the above documents discloses or teaches the therapeutic agent for inflammation or allergic diseases using the extract of Oryxpine.

Thus, the present inventors conducted an experiment to inhibit NO production using LPS-stimulated rat peritoneal macrophages (Experimental Example 1); Inhibition of TNF-a production (Experimental Example 2); Test for the inhibition of histamine secretion induced by Compound 48/80 in mast cells (Experimental Example 3); And DNCB-induced atopic dermatitis animal model experiments, the present inventors have accomplished the present invention by confirming that they have excellent efficacy against inflammation and allergic diseases, especially atopic dermatitis and allergic dermatitis.

According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating an inflammatory or allergic disease comprising an extract of Aspergillus as an active ingredient.

As described above, the fowl chrysanthemums include imported products such as Korean, and Philippine, Thai, Indonesian, Indian, Japanese, and Chinese, and preferably Korean or Chinese.

The extracts defined herein include extracts which are soluble in water, alcohol, lower alcohols such as methanol, ethanol, butanol or a mixture thereof, preferably water or water and ethanol extract.

As used herein, the term "inflammation" as used herein refers to an inflammatory disease such as dermatitis, atopy, conjunctivitis, periodontitis, rhinitis, otitis, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, ), Rheumatoid arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, hay fever, tendinitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis and acute and chronic inflammatory diseases But is not limited thereto.

Allergies as defined herein are allergic rhinitis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, insect allergies, food allergies or drug allergies, preferably allergic rhinitis, asthma, Allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, food allergies or drug allergies, more preferably atopic dermatitis or contact dermatitis.

Hereinafter, a production method for obtaining the extract of the present invention will be described in detail.

For example, the extract of the present invention may be prepared by washing and drying the oyster, then washing it with water, alcohol, C ₁ To C ₄ lower alcohols or a mixed solvent thereof, preferably water or a mixed solvent of water and ethanol, more preferably water as an extraction solvent, at a reaction temperature of about 10 to 120 ° C, preferably 20 to 110 ° C For example, 1 to 10 times, preferably 1 to 10 times, by conventional extraction methods such as room temperature extraction method, heat extraction method, ultrasonic extraction method and reflux extraction method for about 30 minutes to 6 days, preferably 1 hour to 48 hours, A second step of repeating extraction 2 to 7 times; A third step of filtrating and concentrating the extract obtained in the above step under reduced pressure; And the fourth step of lyophilizing the concentrated extract at about -50 ° C to -30 ° C for about 24 to 72 hours to obtain an extract of the present invention.

Accordingly, the present invention provides a pharmaceutical composition and a health functional food for the prevention and treatment of inflammation or allergic diseases containing the extract of Aspergillus oryzae as an active ingredient, obtained by the above production method and the above-mentioned production method.

Inhibition of NO production using LPS-stimulated rat peritoneal macrophages (Experimental Example 1); Inhibition of TNF-a production (Experimental Example 2); Test for the inhibition of histamine secretion induced by Compound 48/80 in mast cells (Experimental Example 3); And DNCB-induced atopic dermatitis animal model experiments, it has been confirmed that the compounds have excellent efficacy against inflammation and allergic diseases, particularly atopic dermatitis and allergic dermatitis, and thus are useful for the treatment and prevention of inflammation or allergic diseases.

The composition of the present invention contains the herbal extract in an amount of 0.1 to 50% by weight based on the total weight of the composition.

However, the composition is not limited thereto, and may vary depending on the condition of the patient, the type of disease, and the progress of the disease.

Compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions.

The composition containing the extract according to the present invention may be formulated in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions, Examples of carriers, excipients and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The preferred dosage of the extract of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract is preferably administered at a dose of 0.01 mg / kg to 10 g / kg per day, preferably 1 mg / kg to 1 g / kg per day. The administration may be carried out once a day or divided into several doses. Therefore, the dose is not intended to limit the scope of the present invention in any aspect.

The composition of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like in various routes. All modes of administration may be expected, including, for example, oral and rectal, or intravenous.

The present invention also provides a health functional food for preventing or ameliorating an inflammatory or allergic disease comprising an extract of Aspergillus oryzae as an active ingredient.

The health functional food containing the extract of the present invention can be used variously for medicines, foods and beverages for prevention and improvement of inflammation or allergic diseases. Examples of the foods to which the extract of the present invention can be added include various foods, beverages, gums, tea, vitamin complexes, health supplements and the like, and they can be used as powders, granules, tablets, capsules or beverages have.

&Quot; Health functional food "as defined herein means food prepared and processed using raw materials or ingredients having functionality useful to the human body in accordance with Law No. 6727 on Health Functional Foods." Functional " Structure and function of the nutrient to control or physiological effects, such as to obtain a beneficial effect for health is intended to eat.

The health functional food for preventing or ameliorating the inflammatory or allergic diseases of the present invention contains 0.01 to 95% by weight, preferably 1 to 80% by weight, of the extract, based on the total weight of the composition.

For the purpose of preventing or ameliorating an inflammatory or allergic disease, it is also possible to use pharmaceutical dosage forms such as powders, granules, tablets, capsules, pills, suspensions, emulsions and syrups or healthful functional foods such as tea bags, Can be manufactured and processed.

The present invention also provides a health supplement for preventing or ameliorating an inflammatory or allergic disease comprising an extract of Aspergillus oryzae as an active ingredient.

The present invention also provides a food or food additive for preventing or ameliorating an inflammatory or allergic disease comprising an extract of Aspergillus oryzae as an active ingredient.

In addition, the above health functional foods may further include food additives, and whether or not they are suitable as "food additives" may be added to the relevant items in accordance with the general provisions of the Food Additives Ordinance approved by the Food and Drug Administration Shall be determined according to the relevant standards and standards.

Examples of the products listed in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, coloring matter, licorice extract, crystalline cellulose, guar gum, Sodium laurate, sodium glutamate preparation, noodles-added alkaline agent, preservative agent, tar pigment preparation and the like.

Examples of the functional food containing the extract of the present invention include confectionery ice cream such as bread, rice cakes, dried fruits, candy, chocolate, chewing gum and confectionery, ice cream products such as ice cream, ice cream powder, low fat milk, Processed products such as processed oil, goat milk, fermented oil, butter oil, concentrated oil, yogurt cream, butter oil, natural cheese, processed cheese, milk powder, milk products, meat products such as hamburger meat products, ham , Fish oil products such as sausages, bacon, etc. Fish products such as noodles, noodles, noodles, noodles, noodles, luxury noodles, improved noodles, noodles such as frozen noodles, pasta, vegetable beverages, Seasonings such as beverages such as soy sauce, miso, kochujang, chunchu, chonggukjang, mixed berries, vinegar, sauce, tomato ketchup, curry, dressing, Lean, shortening, and pizza.

The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.); Disaccharide, (e.g., maltose, sucrose, etc.); And polysaccharides (for example, dextrin, cyclodextrin and the like), and sugar alcohols such as xylitol, sorbitol and erythritol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

In addition, the extract of the present invention can be added to food or beverage for the purpose of preventing the objective disease. At this time, the amount of the extract in the food or beverage may be 0.01 to 15% by weight of the total food, and the health beverage composition may be added in a proportion of 0.02 to 5 g, preferably 0.3 to 1 g, based on 100 ml .

The extract according to the present invention, which is added to foods containing beverages in the course of manufacturing the health functional food, can be appropriately added or decreased as needed.

The extract of Oryxpans according to the present invention was an experiment for inhibiting NO production using LPS-stimulated rat peritoneal macrophages (Experimental Example 1); Inhibition of TNF-a production (Experimental Example 2); Test for the inhibition of histamine secretion induced by Compound 48/80 in mast cells (Experimental Example 3); And DNCB-induced atopic dermatitis animal model experiments, it can be used for the treatment and prevention of inflammation or allergic diseases by confirming that it has excellent efficacy against inflammation and allergic diseases, especially atopic dermatitis and allergic dermatitis.

1 is a graph showing the effect of the extract of the present invention on NO production in intraperitoneal macrophages induced by LPS induced rats;
2 is a graph showing the effect of the extract of the present invention on the production of TNF-a in rat peritoneal macrophages induced by LPS;
Figure 3 is a graph showing the effect of the extract of the present invention on histamine inhibition in mast cells induced by Compound 48/80;
4: photograph showing the effect of the extract of the present invention (single dose administration) on skin changes in an atopic dermatitis animal model induced by DNCB;
5: photograph showing the effect of the extract of the present invention (concentration-dependent dose administration) on skin changes in an atopic dermatitis animal model induced by DNCB;
FIG. 6 is a graph showing the effect of the extract of the present invention (single-dose administration) through the scratching behavior test in an animal model of localized pruritus induced by DNCB;
Figure 7 is a graph showing the effect of the extract of the present invention (concentration-dependent dose administration method) on the amount of appeal through scratching behavior test in an animal model of localized pruritus induced by DNCB;
FIG. 8: Histopathological histology of H & E-stained tissue sections of the extract of the present invention (single dose administration) in an atopic dermatitis animal model induced by DNCB;
FIG. 9: Tissue cross-sectional photograph of H & E stain histopathologically taken in an animal model of atopic dermatitis induced by DNCB, in which the extract of the present invention (concentration-dependent dose administration method) was orally administered.
Figure 10: Experimental result of the effect of oral administration of the extract of the present invention (concentration-dependent dose administration method) on mouse body weight in an atopic dermatitis animal model induced by DNCB (here, Nor; normal group, DNCB; DNCB 100 mg / kg; MYC_200; 200 mg / kg; Dex; dexamethasone; Eli; elidel cream).

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided to further understand the present invention, and the present invention is not limited by the examples.

Example 1 Preparation of Water Extract

1000 ml of purified water (10 times (v / w)) was added to 100 g of dry oysters, and the mixture was refluxed for 10 hours at 80 to 100 ° C. The extract was filtered under reduced pressure and the filtrate was concentrated under reduced pressure (EYELA, N-2100, JAPAN) (13% yield) was obtained and used as a sample of the following experimental example (hereinafter referred to as MYC-1W).

Example 2 Preparation of 30% Ethanol Extract

(V / w) of a mixed solvent of 30% ethanol in an amount of 10 times (v / w) was added to 100 g of the dried oyster, and the mixture was refluxed for 10 hours at 80-100 ° C. The filtrate was filtered under reduced pressure and dissolved in a vacuum concentrator (EYELA, N-2100, JAPAN ) To obtain 23.5 g (yield: 23.5%) of 30% ethanol extract as an oily product, which was used as a sample of the following experimental example (hereinafter referred to as MYC-1E)

<Experimental Example 1> Inhibitory effect of NO production on macrophage group

In order to confirm the anti-inflammatory effect of the samples of the above examples, the inhibitory effect on the NO production in the macrophage group was experimented as follows by applying the method described in the literature (Molecular Immunology, Volume 46, Issue 1112, July 2009, Pages 2413 -2418).

The animals were divided into two groups according to the temperature condition of 20 ° C to 24 ° C, 60% to 70% of the humidity condition and 12 hours Day and night, and water and diet were freely consumed. Macrophage primary cells (2 × 10 ⁶ cells / ml) were cultured in serum starvation medium and used for the experiment after the peritoneal macrophages were separated from the animals by saline washing method. After incubation for 18 hours, the cells were treated with LPS (0.5 ug / ml, L2630, Sigma) and the samples were incubated for 1 hour with 1% sulfanilamide, 0.1% naphthyl-ethylenediamine dihydrochloride, 2% phosphoric acid, Promega, USA). Lt; / RTI >

As a result, the MYC-1W & MYC-1E treatment group inhibited NO production by about 21% at a concentration of 200 ug / ml compared with the LPS-stimulated rat peritoneal macrophage group. (See Fig. 1).

< Experimental Example 2> Macrophage TNF -a inhibitory effect

In order to confirm the antiinflammatory effect of the samples of the above examples, the inhibitory effect of TNF-a production in the macrophage group was examined by applying the method described in the literature (Molecular Immunology, Volume 46, Issues 1112, July 2009, Pages 2413-2418)

In order to observe the anti-inflammatory effect, the amount of TNF-a released into the culture filtrate of the peritoneal macrophages of LPS-stimulated rats was examined by ELISA (R & D) method.

As a result, the MYC-1W & MYC-1E treatment group showed a decrease of up to 16.2% at a concentration of up to 200 ug / ml of TNF-α production compared with the LPS-stimulated rat peritoneal macrophage group. (See Fig. 2)

Experimental Example 3 Inhibitory Effect of Compound 48/80 on Histamine Secretion in Mast Cells

In order to confirm the antiallergic effect of the samples of the above examples, the inhibitory effect of histamine secretion induced by Compound 48/80 in mast cells by applying the method described in the literature was tested as follows. ( European Journal of Pharmacology, Volume 612, Issues 13, 10 June 2009, Pages 122-130 )

After injecting 30 ml of Tyrode buffer solution (137 mM NaCl, 5.3 mM glucose, 12 mM NaHCO3, 2.7 mM KCl, 0.3 mM NaH2PO4, and pH 7.4 sigma) into the peritoneal cavity of the rats and massage the abdomen for about 90 seconds, Carefully opened and collected Tyrode buffer solution B containing peritoneal cells with a Pasteur pipette. (European Journal of Pharmacology, Volume 612, Issues 13, 10). The cells were then centrifuged at 150 xg for 10 minutes by centrifugation (Hanil, 416100) to precipitate the cells. The precipitated cells were pipetted with Tyrode buffer solution June 2009, Pages 122-130). The mast cells were obtained by the percoll density gradient method.

In order to examine the antiallergic effect of the sample obtained in Example 1, histamine release inhibitory effect was observed using mast cells known as the causative cells of allergic reactions.

In order to induce degranulation of mast cells, compound 48/80 (10 ug / ml, Sigma) was administered to cultured cells simultaneously with the control (10 ug / ml, sigma)

Compound 48/80 alone increased histamine release compared to normal mast cells, and histamine release from MYC-1W & MYC-1E treated group showed the best effect at a concentration of 50 ug / ml and suppressed by more than 50.3% . (See Fig. 3)

<Experimental Example 4> Evaluation of effects on skin changes in an animal model of atopic dermatitis induced by DNCB

In order to confirm the antiallergic effect of the samples of the above examples, the effect of each skin change in an atopic dermatitis animal model induced by DNCB by applying the method described in the literature was examined as follows (Journal of Acupuncture and Meridian Studies, Volume 6, Issue 2, April 2013, Pages 98-109)

4-1. Materials and reagents

Dexamethasone, acetone, olive oil, and 1-chloro 2,4-dinitrobenzene (DNCB) were purchased from Sigma Chemical Co., Ltd. (Sigma, Louis, MO, USA).

4-2. Experimental procedure and results (single dose administration method)

The DNCB-induced atopic dermatitis animal model was used for 5 weeks in ICR mice (male, 23-25 g, purchased from Sam Taco) for 1 week in an animal laboratory. Five groups per group were placed under the temperature condition of 20 to 24 캜, the humidity condition of 60% to 70% and the daylight condition of 12-hour cycle, and the water and the diet were freely taken. The diet used was a solid diet (Samyang Feed, Korea) and the lighting was adjusted at a 12-hour cycle.

The dorsal area of the mouse was cleaned and allowed to stand for 24 hours so that the micro-wounds of the skin were cured. 200 μl of a 2.5% DNCB solution (237329, Sigma) prepared by mixing acetone and olive oil at a ratio of 3: 1 was applied to the back region to induce an immunization reaction. After 3 days, once every 3 days, 150 1.0 of 1.0% DNCB solution was applied to the back region to induce atopic dermatitis. After applying the DNCB solution twice to the back area, scabs became worsened due to the formation of scab, and the scar on the back area began to peel off, resulting in atopic dermatitis. After 4 treatments, atopic dermatitis was caused to serious condition. To prevent errors caused by natural healing, 150 1.0 of 1.0% DNCB solution was applied to the back of the mouse once every three days.

The drug administration was oral administration of MYC-1W (200 mg / kg) and MYC-1E (200 mg / kg) for 3 weeks and the degree of disease treatment was photographed using a microscope (leica, M50).

As shown in FIG. 4, the DNCB-treated group exhibited severe wounding, erosion, keratinization, and elimination, but it was found that the test group in which MYC-1W and MYC- (See FIG. 4). As shown in FIG. 4,

4-3. Experimental procedure and results (concentration-dependent administration method)

Five-week-old ICR mice were purchased and adapted for one week before use. The day before the application of the test substance, the animal's back was removed from the neck to the pelvis and left to stand for 24 hours to heal the wound. 200 μl of a 1% DNCB solution (237329, Sigma) prepared by mixing acetone and olive oil at a ratio of 3: 1 was applied to the back region to induce an immunization reaction. After 4 days, once every 3 days, 150 0.5 of 0.5% DNCB solution was applied to the back region to induce atopic dermatitis. After applying the DNCB solution twice to the back area, scabs became worsened due to the formation of scab, and the scar on the back area began to peel off, causing atopic dermatitis. After 4 treatments, atopic dermatitis was caused to serious condition. To prevent errors caused by natural healing, 150 1.0 of 1.0% DNCB solution was applied to the back of the mouse once every three days.

The drug was administered orally at a dose of 10, 50, 100, or 200 mg / kg for 5 weeks at the same time as the second DNCB application, orally for 4 weeks at a dose of 2.5 mg / kg of dexamethasone, 100ul each for 4 weeks. The degree of treatment of the disease was compared using a microscope (leica, M50).

As shown in FIG. 5, the DNCB-treated group showed progression of severe wounds, erythema and keratinization and elimination. However, in the experimental group administered with MYC-1W for 5 weeks after induction of dermatitis, The severity of the symptoms was visually observed. Especially, the most improved symptom of dermatitis was Elidel ointment, followed by MYC_100mg / kg (MYC-1W) group. (See Fig. 5 = replaced Fig. 3)

<Experimental Example 5> Inhibition of inflammation in an animal model of atopic dermatitis induced by DNCB at a local site

Scratching behavior experiments were performed as follows to test the inhibitory effect of DNCB-induced atopic dermatitis on local pruritus in the samples obtained in the above examples.

5-1. Experimental procedure and results (single dose administration method)

One hour before the start of the experiment, The animals were transferred to an observation chamber and stabilized after administration of the drug. The drug administration was oral administration of MYC-1W & MYC-1E (200 mg / kg), respectively. After 30 minutes of oral administration, 150 μl of 1% DNCB was applied to the back of the experiment in the same conditions as the experimental conditions. After 30 minutes, recording was carried out for 20 minutes at 60 minutes by a recorder, and the number of scratching the itch was counted by double- Respectively.

As a result of this experiment, as shown in FIG. 6, scratching frequency (average 89 times) was increased in DNCB alone treatment group. However, in MYC-1W & MYC-1E treated group, these symptoms were significantly reduced by 67 times compared to the control group. (See Fig. 6)

5-2. Experimental procedure (concentration-dependent administration method)

One hour before the start of the experiment, The animals were transferred to an observation chamber and stabilized after administration of the drug. The drug was administered orally at a concentration of 10, 50, 100, 200 mg / kg for 5 weeks, orally for 4 weeks at a concentration of 2.5 mg / kg of dexamethasone, and treated with 100ul of the oily patch for 4 weeks . After 30 minutes of oral administration, 150 μl of 1% DNCB was applied to the back of the mice in the same conditions as the experimental conditions. After 30 minutes, the mice were photographed for 20 minutes in a laboratory for 3 minutes every 3 minutes for 60 minutes. And the number of times of behavior such as scratching was counted by the double blind method.

As a result, the scratching frequency of the DNCB alone group was increased while the MYC-treated group (MYC-1W) was reduced to the concentration of 100 mg / kg, as shown in FIG. The dexamethasone treated group had a smaller number of times than the control group, but the decrease rate was smaller than that of the MYC treated group. It was also found that the number of scratches was significantly decreased in the experimental group (Eli) treated with the atelast treatment, Elidel ointment. This suggests that the physical properties of the ointment seemed to reduce the feeling of itching, and MYC was more effective than Dex in oral administration

<Experimental Example 6> Histopathological findings of MYC-1W & MYC-1E in an atopic dermatitis animal model

Experiments were carried out as follows to confirm the effect of MYC-1W & MYC-1E on histopathological morphology in the atopic dermatitis animal model of the samples obtained in the above examples.

6-1. Experimental procedure and results (single dose administration method)

The skin tissue of the mouse (Sematago, male, 4 weeks old, 26g) of Experimental Example 4 was biopsied 1.5x1.5 cm ² around the circumference of the back, fixed in 4% formaldehyde solution (F8775, Sigma) Paraffin blocks were prepared through a series of procedures and cut into skin sections at intervals of 5 μm. Hematoxylin & eosin (HHS16, Sigma) was used for histological examination.

The MYC-1W and MYC-1E treated groups showed that the surface layer of the skin layer was uniform and the surface layer was smoothly formed as compared with the control group, and it was found that the MYC-1W and MYC-1E were usefully used in the treatment of atopy (See Fig. 8).

6-2. Experimental procedure and results (concentration-dependent administration method)

The skin tissue of the mouse (Sematago, male, 4 weeks old, 26g) of Experimental Example 4 was biopsied 1.5x1.5 cm ² around the circumference of the back, fixed in 4% formaldehyde solution (F8775, Sigma) Paraffin blocks were prepared through a series of procedures and cut into skin sections at intervals of 5 μm. Hematoxylin & eosin (HHS16, Sigma) was used for histological examination. The overall condition of the skin was observed with an optical microscope (leica, M50).

Histological examination of the dorsal skin tissue of the mice revealed that the degree of thickening of the epithelium was significantly improved by DNCB treatment, but the degree of thickening of the epithelium was significantly reduced by treatment with the test substance. As a result of the skin biopsy, it was confirmed that the Eli-treated group showed the most reduction of the inflammation in the skin as in the above data, and it was confirmed that the effect was more conspicuous at the concentration of MYC 100 mg / kg (MYC-1W) Reference)

< Experimental Example 7> Weight change experiment

Experiments were conducted as follows to confirm the effects of weight change in the atopic dermatitis animal model of the samples obtained in the above Examples.

The DNCB-induced atopic dermatitis animal model was used for 5 weeks in ICR mice (male, 23-25 g, purchased from Sam Taco) for 1 week in an animal laboratory. Five groups per group were placed under the temperature condition of 20 to 24 캜, the humidity condition of 60% to 70% and the daylight condition of 12-hour cycle, and the water and the diet were freely taken. The diet used was a solid diet (Samyang Feed, Korea) and the lighting was adjusted at a 12-hour cycle. Five - week - old ICR mice were purchased and adapted for one week, and the experiment was performed for a total of 4 weeks, and the body weight was determined on a weekly basis.

As a result, the body weight of each experimental group increased with time except for dexamethasone. (See Fig. 10)

The formulation of the composition containing the extract of the present invention is described above, but the present invention is not intended to be limited thereto but is specifically described.

Preparation Example 1. Preparation of powder

MYC-1W ----------------------------------------------- --- 20 mg

Lactose ------------------------------------------------- - 100 mg

Talc ------------------------------------------------- --- 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation Example 2. Preparation of tablets

MYC-1E ----------------------------------------------- --- 10 mg

Corn starch --------------------------------------------- 100 mg

Lactose ------------------------------------------------- - 100 mg

Magnesium stearate -------------------------------------- 2 mg

After mixing the above components, tablets are prepared by tableting according to a conventional tablet preparation method.

Formulation Example 3. Preparation of capsules

MYC-1E ----------------------------------------------- --- 10 mg

Crystalline cellulose ---------------------------------------- 3 mg

Lactose ---------------------------------------------- 14.8 mg

Magnesium stearate 0.2 mg < RTI ID = 0.0 >

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Formulation Example 4. Preparation of injection

MYC-1W ----------------------------------------------- --- 10 mg

Mannitol ------------------------------------------------- 180 mg

Sterile sterile distilled water for injection ------------------------------------ 2974 mg

Na2HPO4, 12H2O ------------------------------------------- 26 mg

(2 ml) per 1 ampoule according to the usual injection preparation method.

Formulation Example 5. Preparation of a liquid preparation

MYC-1W ----------------------------------------------- --- 20 mg

Isseong Party ------------------------------------------------ - 10 g

Mannitol ------------------------------------------------- --- 5 g

Purified water ------------------------------------------------- - Suitable amount

Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.

Formulation Example 6. Preparation of Healthy Foods

MYC-1E ----------------------------------------------- 1000 mg

Vitamin mixture -------------------------------------------

Vitamin A Acetate ------------------------------------ 70 g

Vitamin E ---------------------------------------------- 1.0 mg

Vitamin B1 -------------------------------------------- 0.13 mg

Vitamin B2 -------------------------------------------- 0.15 mg

Vitamin B6 --------------------------------------------- 0.5 mg

Vitamin B12 -------------------------------------------- 0.2 g

Vitamin C ----------------------------------------------- 10 Mg

Biotin ------------------------------------------------- 10 [mu] g

Nicotinic acid amide 1.7 mg

Folic acid ------------------------------------------------- - 50 [mu] g

Calcium pantothenate ----------------------------------------- 0.5 mg

Inorganic mixture -------------------------------------------

Ferrous sulfate 1.75 mg < RTI ID = 0.0 >

Zinc oxide - 0.82 mg

Magnesium carbonate ----------------------------------------- 25.3 mg

Potassium phosphate monohydrate 15 mg

Secondary calcium phosphate -------------------------------------------- 55 mg

Potassium citrate --------------------------------------------- 90 mg

Calcium carbonate ---------------------------------------------- 100 mg

Magnesium chloride ----------------------------------------- 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Formulation Example 7. Preparation of health drink

MYC-1E ----------------------------------------------- 1000 mg

Citric acid ----------------------------------------------- 1000 mg

Oligosaccharide ----------------------------------------------- 100 g

Plum concentrate ----------------------------------------------- 2 g

Taurine ------------------------------------------------- - 1 g

Purified water was added.

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, &Lt; / RTI >

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims

A pharmaceutical composition for preventing or treating an inflammatory or allergic disease comprising an extract of Aspergillus oryzae as an active ingredient.

The method according to claim 1,
The pharmaceutical composition according to any one of claims 1 to 3, wherein the oyster shell is Korean, and a Philippines, a Thai, an Indonesian, an Indian, a Japanese, or a Chinese.

The method according to claim 1,
Wherein the extract is an extract soluble in water, alcohol, methanol, ethanol, butanol or a mixed solvent thereof.

The method according to claim 1,
The inflammation is selected from the group consisting of conjunctivitis, periodontitis, rhinitis, otitis, sore throat, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, Wherein the disease is selected from the group consisting of inflammatory bowel disease, tendinitis, nephritis, neuritis, perianal inflammation, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, multiple sclerosis and acute and chronic inflammatory diseases.

The method according to claim 1,
Wherein said allergy is a disease selected from hypersensitivity, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, insect allergies, food allergies or drug allergies.

A health functional food for prevention or improvement of inflammation or allergic diseases containing an extract of Aspergillus oryzae as an active ingredient.

The method according to claim 6,
The health functional food is a health functional food in the form of a powder, a granule, a tablet, a capsule, a pill, a suspension, an emulsion, a syrup, a tea bag, an oil-

A dietary supplement for prevention or improvement of inflammation or allergic diseases which contains an extract of Aspergillus oryzae as an active ingredient.

Foods for prevention or amelioration of inflammatory or allergic diseases which contain an extract of Aspergillus oryzae as an active ingredient.

A food additive for preventing or ameliorating an inflammatory or allergic disease comprising an extract of Aspergillus oryzae as an active ingredient.